Roche’s decommissioning of its former Co Clare manufacturing site has become one of Europe’s largest remediation efforts, with costs now totalling €150.5m over five years. The Swiss pharma group recorded a €54.9m loss in 2024 as remediation spend continued to mount, underscoring the scale and long-term financial weight of environmental obligations in site exits. For the industry, it is a sharp reminder that the true cost of winding down operations can extend far beyond closure — both in capital and in strategic impact.

Read the full article here.